Group 1 - The privatization offer for Kangji Medical is led by Chairman Zhong Ming, TPG, and Qatar Investment Authority (QIA), with a proposed price of HKD 9.25 per share, valuing the company at approximately USD 1.4 billion [1][2] - The company has faced continuous pressure on its stock price and long-term liquidity issues, which have limited its ability to raise funds from the stock market [2] - The company was listed on the Hong Kong Stock Exchange in June 2020, with an initial offering price of HKD 13.88 per share, but the stock price had dropped to HKD 8.42 per share before the privatization announcement, indicating a significant decline [2] Group 2 - The offerors believe that maintaining the company's listing incurs administrative, compliance, and other costs, which provide limited benefits given the current market conditions and regulatory uncertainties [2] - Following the announcement of the privatization, the stock performance was relatively flat, with minor fluctuations observed on August 13, 2023 [2] - After the privatization, the Zhong couple will retain a 40% stake in the ultimate holding company, maintaining their position as the largest shareholders [1]